The Efficacy of Burosumab Treatment for Hypophosphatemic Rickets: Systematic Review

References (25)

1. 1 Rayyan—a web and mobile app for systematic reviews [DOI]
2. 2 Burosumab Therapy in Children with X-Linked Hypophosphatemia [DOI]
3. 3 Therapeutic management of hypophosphatemic rickets from infancy to adulthood [DOI]
4. 4 Randomized trial of the anti-FGF23 antibody KRN23 in X-linked hypophosphatemia [DOI]
5. 5 Hypophosphatemia leads to rickets by impairing caspase-mediated apoptosis of hypertrophic chondrocytes [DOI]
6. 6 Hypophosphatasia: An overview For 2017 [DOI]
7. 7 Hypophosphatemia: the common denominator of all rickets [DOI]
8. 8 Efficacy and safety of burosumab in children aged 1–4 years with X-linked hypophosphataemia: a multicentre, open-label, phase 2 trial [DOI]
9. 9 Effect of Burosumab Compared With Conventional Therapy on Younger vs Older Children With X-linked Hypophosphatemia [DOI]
10. 10 Burosumab treatment in adults with X-linked hypophosphataemia: 96-week patient-reported outcomes and ambulatory function from a randomised phase 3 trial and open-label extension [DOI]
11. 11 Benefit of burosumab in adults with X-linked hypophosphataemia (XLH) is maintained with long-term treatment [DOI]
12. 12 Burosumab in management of X-linked hypophosphataemia: a retrospective cohort study of growth and serum phosphate levels [DOI]
13. 13 Hypophosphatemic Rickets: Lessons from Disrupted FGF23 Control of Phosphorus Homeostasis [DOI]
14. 14 Hypophosphatemic rickets [DOI]
15. 15 Oral Iron Replacement Normalizes Fibroblast Growth Factor 23 in Iron-Deficient Patients With Autosomal Dominant Hypophosphatemic Rickets [DOI]
16. 16 Body composition and cardiometabolic health of pediatric patients with X-linked hypophosphatemia (XLH) under burosumab therapy [DOI]
17. 17 Vitamin D-Dependent rickets Type II with alopecia: A rare case report [DOI]
18. 18 Switching from conventional therapy to burosumab injection has the potential to prevent nephrocalcinosis in patients with X-linked hypophosphatemic rickets [DOI]
19. 19 Burosumab versus conventional therapy in children with X-linked hypophosphataemia: a randomised, active-controlled, open-label, phase 3 trial [DOI]
20. 20 Linear growth of children with X-linked hypophosphatemia treated with burosumab: a real-life observational study [DOI]
21. 21 Different Efficacy of Burosumab on Physical Performance and Serum Phosphate in Adult Patients with X-Linked Hyphophosphatemic Rickets during the First Six-Month of Treatment [DOI]
22. 22 Hypophosphatemia Leads to Rickets by Impairing Caspase-Mediated Ap-optosis of Hypertrophic Chondrocytes [DOI]
23. 23 Journal of Pediatric Endocrinology and Metabolism [DOI]
24. 24 Current Osteoporosis Reports [DOI]
25. 25 Fibroblast Growth Factor 23 [DOI]

Cited by 0

No indexed citations yet.

Related research

• A Randomized Placebo Controlled Study to Determine the Efficacy of Oral Diclofenac Sodium in the Treatment of Symptomatic Osteoarthritis of the Knee in Nnewi, South Eastern Nigeria — shares topic coverage
• Bacteriological and Fungal Evaluation of Three Brands of Disinfectants Sold in Calabar Municipality, Cross River State — shares topic coverage
• Drug Interactions, Safety and Efficacy of Probiotics — shares topic coverage
• The Efficacy of the Volume of Hyperbaric Bupivacaine Used and Its Influence on Spinal Anaesthesia Induced Hypotension during Caesarean Section — shares topic coverage
• A Comparison of Efficacy of Two Brands of Enoxaparin in COVID-19 Patients: A Pilot Study — shares topic coverage